Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 31259

AbstractMaterial and MethodsResultsDiscussionConclusionReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Original article / research
Year : 2024 | Month : November | Volume : 18 | Issue : 11 | Page : EC01 - EC06 Full Version

Role of Angiogenesis and Endothelial-mesenchymal Transition in Bone Marrow Fibrosis Associated with Haematopoietic Neoplasms: A Cross-sectional Immunohistochemical Analysis


Published: November 1, 2024 | DOI: https://doi.org/10.7860/JCDR/2024/70304.20248
Shweta Agarwal, Shruti Sharma, Monal Trisal, Zeeba S Jairajpuri, Sujala Kapur, Sumita Saluja, Purnima Paliwal

1. Resident, Department of Pathology, ICMR, National Institute of Pathology, Safdarjung Hospital Campus, New Delhi, India. 2. Scientist E, Department of Pathology, ICMR, National Institute of Pathology, Safdarjung Hospital Campus, New Delhi, India. 3. Assistant Professor, Department of Pathology, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard University, New Delhi, India. 4. Professor, Department of Pathology, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard University, New Delhi, India. 5. Scientist E, Department of Pathology, ICMR, National Institute of Pathology, Safdarjung Hospital Campus, New Delhi, India. 6. Professor, Department of Pathology, ICMR, National Institute of Pathology, Safdarjung Hospital Campus, New Delhi, India. 7. Scientist D, Department of Pathology, ICMR, National Institute of Pathology, Safdarjung Hospital Campus, New Delhi, India.

Correspondence Address :
Dr. Zeeba S Jairajpuri,
Professor, Department of Pathology, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard University, New Delhi-110062, India.
E-mail: jairajpurizs@gmail.com

Abstract

Introduction: The bone marrow examination is an essential investigation in the diagnosis and management of many haematological disorders. The integration of all investigations, including peripheral blood analysis, bone marrow aspirate, and trephine biopsy findings, along with supplementary tests such as immunophenotyping, cytogenetic analysis, and molecular genetic studies, is crucial for arriving at a final diagnosis.

Aim: To assess the presence of reticulin fibres in bone marrow biopsy sections in haematological malignancies, to evaluate the grade of BMF associated with haematological malignancies and to assess the role of angiogenesis using IHC markers in various haematological malignancies.

Materials and Methods: A cross-sectional study was conducted in the Department of Pathology at the National Institute of Pathology, Safdarjung Hospital, New Delhi, India in 2009 for a duration of 18 months. Thirty-eight patients with a diagnosis of Acute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukaemia (ALL), Chronic Myeloid Leukaemia (CML), and Chronic Lymphoproliferative Disorder (CLPD) were studied. Bone marrow biopsies were taken, fixed in 10% formalin, and decalcified in 10% Ethylene Diamine Tetraacetic Acid (EDTA). Routine paraffin embedding was performed, and serial sections of 4 μm were obtained on poly-L-lysine-coated slides for Immunohistochemistry (IHC) {Vimentin, Vascular Endothelial Growth Factor (VEGF), CD-34, Smooth Muscle Actin (SMA)}. The presence of reticulin fibres in the bone marrow biopsy sections was assessed using two special stains: Gomori’s Silver Impregnation and Masson’s Trichrome. Fibrosis was quantified according to the Baurmeister 0-4 grading system of Bone Marrow Fibrosis (BMF).

Results: The results of the present study suggest that Endothelial to Mesenchymal Transition (EndMT) may play a role in the pathogenesis of BMF. Various grades of fibrosis were observed, with 15 cases (39.47%) in Grade 3, followed by 11 cases (28.95%) in Grade 2, 8 cases (21.05%) in Grade 1, and 4 cases (10.53%) in Grade 4.

Conclusion: BMF was a significant finding even in the early stages of the majority of the lesions studied and was closely linked with angiogenesis. This study showed that angiogenesis plays an important role in the pathogenesis of haematological neoplasms and that VEGF is a prominent stimulus in the majority of these disorders. Additionally, this study suggests that EndMT has a possible role in the pathogenesis of BMF.

Keywords

Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Chronic lymphoproliferative disorder, Chronic myeloid leukaemia, Epithelial

Bone marrow examination is an essential investigation in the diagnosis and management of many haematological disorders. The integration of all investigations, like peripheral blood analysis, bone marrow aspirate, and trephine biopsy findings, along with supplementary tests like immunophenotyping, cytogenetic analysis, and molecular genetic studies, is essential for the final diagnosis. BMF refers to an increase in reticulin or increase in both reticulin and collagen, serving as a useful non specific indicator that the marrow is abnormal. Reticulin is a normal component of bone marrow that may be increased in a wide variety of neoplastic and non neoplastic conditions. The relationship between increase in bone marrow stromal fibres and disease pathology is not well understood but has been the subject of clinical investigations (1),(2). Angiogenesis, the formation of new blood vessels from existing vasculature, has been associated with the growth, dissemination, and metastasis of solid tumours (3). Although it is suggested that angiogenesis plays a role in the development of fibrosis, only a few studies have correlated it with the extent of fibrosis in the marrow. However, some authors have demonstrated a correlation between angiogenesis and the degree of reticulum fibrosis in cases of Chronic Idiopathic Myelofibrosis (CIMF) (3).

The proliferation of myofibroblasts is responsible for exaggerated and unchecked extracellular matrix production during the development as well as progression of pathological fibrosis. Myofibroblasts in densely fibrotic tissues arise from the activation of resident fibroblasts, the transformation of epithelial cells into mesenchymal cells (Epithelial-Mesenchymal Transition, or EMT), and the tissue migration of circulating bone marrow-derived fibrocytes (4),(5). Recently, EndMT has emerged as a possible origin of tissue myofibroblasts. EndMT is often categorised as a specialised form of EMT. It is a process in which resident endothelial cells delaminate from an organised cell layer and acquire a mesenchymal phenotype, characterised by the loss of cell-cell junctions, loss of endothelial markers, gain of mesenchymal markers, and acquisition of invasive and migratory properties. These processes are associated with the emergence of mesenchymal markers such as Fibroblast-Specific Protein (FSP1), alpha SMA, and vimentin, along with the downregulation of CD31/PECAM and β-catenin (6).

The present study aimed to assess the presence of reticulin fibres in bone marrow biopsy sections in haematological malignancies, to evaluate the grade of BMF associated with haematological malignancies and to assess the role of angiogenesis using IHC markers in various haematological malignancies.

Material and Methods

A cross-sectional study was conducted in the Department of Pathology at the National Institute of Pathology, Safdarjung Hospital, New Delhi, India, from January 2009 to July 2010. SPPS 18 version was used.

Inclusion criteria: A total of 38 patients with a diagnosis of AML, ALL, Chronic Myeloproliferative Diseases (CMPD), and Chronic Lymphocytic Leukaemia (CLL) were included in this study.

Exclusion criteria: All inadequate biopsies were excluded from the study group.

Bone marrow biopsies performed as part of the investigation for anaemia, which were found to be adequate and normal on histology, were taken as control samples.

Study Procedure

Biopsies were taken and fixed in 10% formalin, then decalcified in 10% EDTA. Processing was performed according to routine paraffin embedding, and serial sections of 4 μm were obtained on poly-L-lysine coated slides for IHC. The presence of reticulin fibres in the bone marrow biopsy sections was assessed using two special stains: Gomori’s Silver Impregnation and Masson’s Trichrome. Fibrosis was quantified according to the Baurmeister’s 0-4 grading system of BMF (7).

• Grade 0-No reticulin fibres demonstrable
• Grade 1-Occasional fine individual fibres and foci of a fine fibre network
• Grade 2-Fine fibre network throughout most of the section; no coarse fibres
• Grade 3-Diffuse fibre network with scattered, thick, coarse fibres but no mature collagen (negative trichrome staining)
• Grade 4-Diffuse, often coarse fibre network with areas of collagenisation (positive trichrome staining)

Immunohistochemistry: All blood vessels were highlighted by staining endothelial cells with an anti-CD34 antibody using the Avidin-Biotin complex method (Diagnostic Bioscience, dilution of 1:50). Antibodies against Vimentin (Biogenix, undiluted) and SMA (Novocastra, dilution of 1:50) were used as mesenchymal markers. Vimentin expression was quantified as the percentage of cells showing vimentin positivity in high-power fields.

To measure bone marrow Microvessel Density (MVD), microvessels stained by CD34 were counted in three hotspots, and the average was reported as MVD. The hotspots were defined as areas of maximum vessel density observed through a 10× power ocular lens. Large vessels and vessels located beneath the periosteum were excluded from the analysis. The method used for counting the microvessels involved selecting areas of highest MVD (hotspots) at 40× magnification, followed by image capture and counting the microvessels in 10 selected fields of each slide at 200× magnification. The countable microvessels were defined according to the criteria established by Weidner N et al., (8).

Statistical Analysis

The mean of MVD was obtained for various subsets of samples and compared with those of the control group using Statistical Package for the Social Sciences (SPSS). Box plots were used to compare the distribution of the different sample sets, and statistical significance was determined using Student’s t-test. To correlate MVD with the grade of fibrosis, linear least squares regression analysis was employed.

Results

Thirty-eight samples from patients with haematological disorders with BMF were included in the study. The diagnosis of these patients ranged from acute leukaemia to chronic myeloproliferative disorders, Chronic Lymphoproliferative Disorders (CLPD), and Myelofibrosis (MF). The distribution of the cases according to histological diagnosis is provided in (Table/Fig 1).

The majority of the patients in the sample set were male, constituting 71.05% of the cases (27 out of 38), while female patients numbered 11, comprising 28.95% of the cases.

Grading of fibrosis was performed in all cases according to a 0-4 grading system. Gomori’s silver impregnation was useful in identifying reticulin fibrosis of grades 1-3, while Masson’s Trichrome stain showed collagen fibrosis (Grade-4). All four grades of fibrosis were observed in the sample set (n=38), with the majority belonging to Grade-3. The distribution of samples across the various grades of fibrosis was as follows: 15 cases (39.47%) in Grade-3, 11 cases (28.95%) in Grade-2, 8 cases (21.05%) in Grade-1, and 4 cases (10.53%) in Grade-4.

Upon further analysis, the distribution of cases in each histological category across the various grades of fibrosis revealed that cases of AML showed an equal distribution of Grade-2 and Grade-3 severity, i.e., three each out of eight cases, whereas in ALL, Grade-1 and Grade-3 showed an equal distribution of three cases each out of a total of seven cases. In CML three out of six cases (50%) exhibited Grade-2 fibrosis, while in CLPDs, four out of nine cases (45%) showed Grade-2 fibrosis. Additionally, in CLPDs, two cases demonstrated focal increases in reticulin (Grade-1), which were primarily concentrated around the nodular infiltrates. In MF, an equal distribution of Grade-3 and Grade-4 fibrosis was observed. Collagen fibrosis was primarily seen in samples of idiopathic MF, as depicted for analysis in (Table/Fig 2).

The vascularity showed a significant increase (p-value<0.001) in all the bone marrow biopsies included in the study compared to the control samples (Table/Fig 3),(Table/Fig 4)a. The majority of the newly formed vessels were found to be tortuous with abnormal branching, and some were composed of only 1-2 endothelial cells.

However, in the individual case analysis, there was a positive correlation in ALL (R2=0.75), CML (R2=0.30), AML (R2=0.40), and CLPD (R2=0.24), but not in MF. In CLPD, the two nodular samples showed a high MVD, but the vessels were primarily concentrated around the nodular infiltrates. Excluding these two samples from the analysis revealed a strong fit of MVD with grade of reticulin (R2=0.69). This observation can be explained by the use of a semiquantitative method for estimation of MVD.

Immunohistochemical studies for endothelial markers (VEGF and CD34) and mesenchymal markers (SMA and Vimentin) were conducted for analysis. VEGF showed crisp granular staining in normal bone marrow biopsies for megakaryocytes and myeloid progenitor cells, whereas erythroid and stromal cells did not express the cytokine. However, VEGF expression was markedly upregulated and was expressed by the leukaemic blasts and stromal cells as well (Table/Fig 5). The findings were expressed as a VEGF score by counting the cells positive for VEGF in three high-power fields and calculating the average (Table/Fig 6). The average VEGF score in bone marrow biopsies of patients with AML, CML, CLPD, and MF was found to be significantly higher compared to the biopsies from control samples. In ALL, however, there was no statistically significant difference in the VEGF score when compared to the control samples. In AML, a high score of 37.5/hpf was observed, with VEGF expressed by the majority of myeloblasts, megakaryocytes, and myeloid progenitor cells (Table/Fig 5)b,d. Similarly, in CML and MF, high scores of 33 and 47.6 per hpf, respectively, were noted, with markedly upregulated expression of VEGF in both myeloid as well as stromal cells (Table/Fig 5)c. In CLPDs, a highly variable pattern of VEGF expression was noted. In samples with diffuse infiltration of the bone marrow, the malignant cells showed strong positivity for VEGF, whereas samples with nodular infiltrates showed scant positivity to completely negative malignant nodules. The overall score obtained for all CLPD samples was 29.9/hpf. Regression analysis between VEGF and the grade of fibrosis in all samples showed a positive correlation (R2=0.40). When analysing individual samples, a positive correlation between VEGF and the grade of fibrosis was found in ALL and CML, but not in ALL and CLPD. In MF, VEGF was found to be independent of the grade of fibrosis.

The expression of CD34 was found in the endothelial cells of large vessels as well as in the micro-vessels in normal bone marrow biopsies. Micro-vessels stained by CD34 were counted in three hotspots, with the average reported as MVD (Table/Fig 7)a. The hotspots were defined as areas of maximum vessel density, and large vessels as well as vessels located beneath the periosteum were excluded from this count. A significant increase in vascularity was noted in all cases of this study compared to the control group (Table/Fig 7)b-d,(Table/Fig 8). The majority of the newly formed vessels were found to be tortuous with abnormal branching, and some were composed of only 1-2 endothelial cells. It was also observed that in the two nodular samples of CLPD, the hotspots were primarily concentrated around the nodular infiltrates.

Regression analysis between MVD and the grade of fibrosis in all samples showed a strong correlation (R2=0.64). However, in individual case analysis, a positive correlation was seen in ALL, CML, AML, and CLPD, but not in MF. Furthermore, a correlation (R2=0.48) was found between VEGF and MVD for all histological types included in this study. The analysis of individual histological types showed a positive correlation between VEGF and MVD in AML and CML, whereas no correlation was noted in ALL and MF. In CLPDs, there was a weak correlation, but an upward trend was observed.

The expression of the mesenchymal marker SMA in the control bone marrow biopsies was limited to the smooth muscle cells of the media of the large bone marrow vessels (Table/Fig 9)a. It was not expressed by the haematopoietic cells or the stromal cells of the marrow. In the study samples, α-SMA was expressed in the pericytes of large vessels and microvessels. Endothelial-to-Mesenchymal Transition (EndMT) has been hypothesised as one of the origins of pericytes in microvessels formed during angiogenesis. Two discrete layers composed of inner endothelial cells and outer pericytes were observed in 10 out of 38 samples across all histological types except CLPDs [Table/Fig-9b-d,10]. In addition, three out of 38 samples showed upregulation of α-SMA in stromal cells as well as myeloid cells. Furthermore, microvessels in MF as well as CML showed α-SMA expression in endothelial cells in two samples each.

Expression of Vimentin in normal bone marrow biopsies was seen in the stromal cells of normal marrow. The current study found upregulated expression of Vimentin in 12 out of 38 cases. Compared to normal bone marrow biopsies that showed positive Vimentin expression in 10-30% of cells per high-power field (hpf), the biopsies with fibrosis showed positive expression of 50-90% per hpf (Table/Fig 11).

Among all the myeloid cells, stromal cells, and megakaryocytes, strong positivity for Vimentin was observed in 12 out of the 38 cases studied. This finding was noted in ALL (1 case), AML (2 cases), CML (2 cases), CLL (4 cases), and MF (3 cases). The samples with increased Vimentin expression showed grades of fibrosis ranging from Grade 1 to Grade 4.

Discussion

BMF is the progressive replacement of haematopoietic cells by reticulin fibres, caused by the acquisition of somatic mutations in the haematopoietic stem cells. The various cellular and molecular mechanisms that drive the progression of BMF remain unclear. BMF is generally observed as a non specific indicator of an abnormal marrow. It results from a variety of aetiologies, including myeloproliferative disorders such as CML, polycythemia vera, and essential thrombocythemia, as well as acute leukaemias (both myeloid and lymphoid), lymphomas, and various other inflammatory causes (7).

The most frequently used grading systems applied to assess MF are essentially based on the Baumeister scale (7), which was modified by Manoharan (9). The European Consensus on grading BMF and the assessment of cellularity (10) simplifies all previous descriptions of fibre scoring (8),(9) by reducing them to four grades, including normal reticulin density. This approach aims to avoid excessive overlap and achieve a higher degree of reproducibility in routine diagnosis, which was adopted in this study. The confusion created in former systems, where normal reticulin was classified as Grade 1, was addressed by classifying normal reticulin as N-normal or Grade 0 (10).

Bone marrow biopsy is seldom performed in the work-up of acute CML, usually only when a dry tap is obtained on bone marrow aspiration. As is evident, data on reticulin fibrosis in these neoplasms is limited, despite the fact that BMF per se has poor prognostic value. The current study documents fibrosis in acute leukaemias (both myeloid as well as lymphoid) at the time of initial diagnosis, ranging from a focal increase in reticulin fibres (Grade 1) to marked fibrosis with scattered coarse fibres (Grade 3). The pathogenesis of AML with BMF remains unclear. It has been suggested that the abnormal proliferation of BMF is a secondary reaction to the clonal proliferation of haematopoietic cells (11) and is characterised by increased deposition of reticulin or collagen fibres. However, BMF, which can be observed in any type of AML, is more frequent in Acute Megakaryocytic Leukaemia (AML-M7) (12). Earlier studies have reported increased reticulin in 35% of AML patients and 57% of ALL patients at presentation (13),(14).

CML, minimal reticulin to advanced collagen fibrosis has been reported earlier in 10-35% of cases at presentation (15). It is now a well known factor that contributes to morbidity and mortality in these patients (15),(16). In the present study, CML samples with fibrosis ranged from Grade-1 to Grade-3. A single case of CML progressing to MF was also seen in this study; however, it has been categorised within the MF group for the uniformity of statistical analysis. The authors suggest the use of bone marrow biopsy as an important tool in the work-up of patients with suspected CML. Bone marrow core biopsy is valuable in the initial staging of CML in approximately 25% of patients suspected of having the disease, as it facilitates the identification of the disease phase or the presence of MF (17). Of the eight samples included in the MF category, seven were in the primary idiopathic category (CIMF). The remaining case was secondary MF progressing from CML after a duration of four years and showed Grade-3 fibrosis. Among the remaining seven cases of CIMF, four cases showed Grade-4 fibrosis, while three cases showed Grade-3 fibrosis.

CLL has been associated with several other malignancies, including transformation to diffuse large B-cell lymphoma and various solid organ neoplasms, with bone marrow involvement in CLL always being secondary. CLL is not frequently associated with primary or secondary bone marrow fibrosis. The association between CLL and Primary Myelofibrosis (PMF) and other Myeloproliferative Neoplasms (MPN) is unusual (18). Fibrosis in CLL is a rare finding and has been well documented only in Hairy Cell Leukaemia (HCL) amongst all the CLPDs (13). There was a predominance of Grade-2 fibrosis in CLL samples (45%). A single case of HCL included in the study showed fibrosis of Grade-3, characterised by a delicate pattern of reticulin fibres closely associated with the tumour cells. The exact pathogenesis of fibrosis in HCL remains debatable, as some studies implicate fibrogenic cytokines as the source of fibrosis, while others suggest the role of fibronectin in the fibrotic process [19,20]. This data reveals that reticulin fibrosis is a prominent finding in both the initial and late stages of the majority of haematological neoplasms, thereby further validating the need to include bone marrow biopsy as well as reticulin staining in the investigations conducted for all leukaemias.

It has been proposed that angiogenesis, which is the formation of new blood vessels from existing vasculature, plays a role in the development of fibrosis in the bone marrow. The majority of the newly formed vessels were found to be tortuous and branched, while some were composed of only one or two endothelial cells. Steurer M et al., demonstrated a correlation between angiogenesis and the degree of reticulin fibrosis in cases of CIMF (3). Present study aimed to evaluate angiogenesis and bone marrow fibrosis across a range of haematological malignancies. A significant increase in MVD was observed in acute leukaemias (both myeloid and lymphoid), chronic leukaemias, and MF was seen (p-value<0.0001). The average MVD for all neoplasms was four to five times that of control samples, and the results were comparable to those of previous studies. Although increased vascularity has been demonstrated in individual studies of these neoplasms, there have been conflicting results in patients with CLL (21),(22),(23). The present study showed markedly increased vascularity in both diffuse as well as nodular types of CLL samples. In addition, the study was able to demonstrate a strong correlation between MVD and the grade of reticulin fibrosis, independent of aetiology (R2=0.68).

Tumour-associated angiogenic factors are produced by tumour cells as well as inflammatory cells, such as macrophages. This angiogenic process is regulated by a close interplay of regulatory molecules, among which VEGF and β-FGF are among the most important. As reported earlier, VEGF expression has been seen in megakaryocytes, myeloid progenitor cells, plasma cells, stromal cells, as well as leukaemic blasts, exhibiting crisp granular positivity (23),(24).

A significantly increased expression of VEGF was observed in AML, CML, CLL, and MF, but not in ALL. These findings strongly indicate the role of VEGF as a prominent angiogenic stimulus in the majority of haematological neoplasms studied, with marked upregulation in most cases, except for ALL (25). Similar trends have been reported in the literature using IHC and/or serum levels of this angiogenic cytokine (26).

The association of MVD with the grade of fibrosis opens the discussion on the possible role of EndMT in the pathogenesis of fibrosis. EndMT is a complex process in which endothelial cells delaminate from an organised cell layer and transdifferentiate into mesenchymal cells (27) (such as pericytes or fibroblasts in this particular setting). During this process, some cells lose endothelial markers and begin expressing mesenchymal markers, such as α-SMA and/or vimentin (27),(28). In addition, a few cells exhibiting bi-phenotypic expression-characterised by the presence of both endothelial and mesenchymal markers-can also be found (28). It has been suggested that fibroblasts may arise from endothelial cells via EndMT as one possible source of origin (22). The current study focused on the use of IHC to evaluate such transitional cells in bone marrow fibrosis (29).

EndMT in bone marrow is not widely reported in the literature. It has been suggested that fibroblasts can arise from endothelial cells via EndMT, as well as from pericytes, which can also undergo EndMT as one of the possible source of origin (30). During this process, it is possible to observe a few transitional cells that co-express endothelial and mesenchymal markers, as demonstrated in in-vitro studies. In-vitro, EndMT can be duplicated by incubating cultured endothelial progenitor cells or spleen-derived endothelial cells with inflammatory cytokines. Megakaryocytes may also be implicated in this process, as EndMT occurs predominantly in the microvessels closest to these cells, and megakaryocyte-derived supernatant fluid can generate the EndMT switch in-vitro (30).

In the current study, normal marrow showed α-SMA marking the myocyte layer around the endothelial cells, whereas Vimentin was positive in the stromal cells and fat cells. This study noted an upregulation of α-SMA in 10 out of 38 samples (26.3%). It was also seen that the expression of α-SMA was independent of the degree of fibrosis and aetiology. Furthermore, transitional cells with co-expression of endothelial and mesenchymal markers were seen in cases of CIMF exhibiting Grade 4 fibrosis. A study reported by Suetterlin R et al., used immunofluorescence along with confocal laser scanning microscopy to demonstrate upregulation of α-SMA in bone marrow samples with fibrosis (31). In contrast to the study by Suetterlin R et al., which showed an increase in the expression of α-SMA with increasing degrees of fibrosis (32), the expression of α-SMA in the present study was found to be independent of the degree of fibrosis and aetiology. Furthermore, the, transitional cells with co-expression of endothelial and mesenchymal markers were seen in samples of CIMF exhibiting Grade 4 fibrosis.

Vimentin is a type III intermediate filament that maintains cell integrity and is involved in cell migration, motility, and adhesion. When overexpressed in solid cancers, vimentin drives EMT and ultimately metastasis. As an organiser of several crucial proteins, vimentin plays a role in attachment, migration, and cell signalling (32),(33),(34). The present study documents increased expression of vimentin in 12 out of 38 samples (31.6%), which included all histological types and almost all grades of fibrosis. Almost all bone marrow cells, including myeloid cells, lymphoid cells, megakaryocytes, as well as stromal cells, were strongly positive for this mesenchymal marker. Although there are studies in the literature that have reported the expression of vimentin in haematopoietic cells, data supporting its role in EndMT in the bone marrow is limited (32).

The results of the present study suggest that EndMT has a possible role in the pathogenesis of bone marrow fibrosis. Although the data is limited, evidence of EndMT was observed in almost all types of histological samples with Grade 1 to Grade 4 fibrosis. The observations from this study open an avenue for exploring EndMT in bone marrow fibrosis using a wider panel of antibodies and potentially incorporating other ancillary techniques.

Limitation(s)

The present study was limited by its small sample size; however, the results of this study open up opportunities for exploring EndMT in bone marrow fibrosis using a wider panel of antibodies and possibly incorporating other ancillary techniques.

Conclusion

BMF was a significant finding, even in the early stages of the majority of the lesions studied, and it was closely linked with angiogenesis. This study demonstrated that angiogenesis plays an important role in the pathogenesis of haematological neoplasms, with VEGF identified as a prominent stimulus in the majority of these disorders. Additionally, the results suggested that EndMT had a possible role in the pathogenesis of BMF. Further evaluation of the role of EndMT in BMF, using a wider panel of antibodies along with molecular studies, will help achieve a better understanding of the pathogenetic mechanisms associated with fibrosis in bone marrow disorders.

References

1.
Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: Pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139(3):351-62. [crossref][PubMed]
2.
Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23(33):8520-30. [crossref][PubMed]
3.
Steurer M, Zoller H, Augustin F, Fong D, Heiss S, Strasser-Weippl K, et al. Increased angiogenesis on chronic idiopathic myelofibrosis: Vascular endothelial growth factor as a prominent angiogenic factor. Hum Pathol. 2007;38(7):1057-64. [crossref][PubMed]
4.
Wynn T. Cellular and molecular mechanisms of fibrosis. J Pathol. 2007;214(2):199- 210. Doi: 10.1002/path.2277. [crossref][PubMed]
5.
Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest. 2007;87(9):858-70. [crossref][PubMed]
6.
Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol. 2011;179(3):1074-80. [crossref][PubMed]
7.
Bauermeister DE. Quantitation of bone marrow reticulin- A normal range. Am J Clin Pathol. 1971;56(1):24-31. [crossref][PubMed]
8.
Weidner N, Semple JP, Welch WR, Folkman J. Tumour angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):01-08. [crossref][PubMed]
9.
Gleitz HFE, Benabid A, Schneider RK. Still a burning question: The interplay between inflammation and fibrosis in myeloproliferative neoplasms. Curr Opin Hematol. 2021;28(5):364-71. Doi: 10.1097/MOH.0000000000000669. PMID: 34232140; PMCID: PMC8373448. [crossref][PubMed]
10.
Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol. 1979;43(2):185-90. [crossref][PubMed]
11.
Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Hematologica. 2005;90(8):1128-32.
12.
Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, et al. Bone marrow fibrosis in myelofibrosis: Pathogenesis, prognosis and targeted strategies. Haematologica. 2016;101(6):660-71. [crossref][PubMed]
13.
Zhang X, Wang F, Yu J, Jiang Z. Significance of bone marrow fibrosis in acute myeloid leukaemia for survival in the real-world. Front Oncol. 2022;12:971082. [crossref][PubMed]
14.
Bain BJ, Clark DM, Lampert IA, Wilkins BS. Bone marrow pathology. 3rd Ed. Blackwell Science, 2001;131-134. [crossref]
15.
Islam A, Catovsky D, Goldman JM, Galton DA. Bone marrow fibre content in acute myeloid leukaemia before and after treatment. J Clin Pathol. 1984;37(11):1259-63. [crossref][PubMed]
16.
Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukaemia. Cancer. 1987;59(10):1739-43. 3.0.CO;2-2>[crossref][PubMed]
17.
Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, et al. Chronic myelogenous leukaemia: A multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985;66(6):1326-35. [crossref][PubMed]
18.
Hidalgo-López JE, Kanagal-Shamanna R, Quesada AE, Gong Z, Wang W, Hu S, et al. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukaemia: Assessment of potential value. Cancer. 2018;124(19):3849-55. [crossref][PubMed]
19.
Darawshy F , Ben-Yehuda A, Atlan K, Rund D. Chronic lymphocytic leukaemia and myelofibrosis. Case Reports in Hematology. 2018;2018:7426739. Available from: https://doi.org/10.1155/2018/7426739. [crossref][PubMed]
20.
Burthem J, Cawley JC. The bone marrow fibrosis of hairy-cell leukaemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells. Blood. 1994;83(2):497-504. [crossref][PubMed]
21.
Shehata M, Schwarzmeier JD, Hilgarth M, Hubmamm R, Duechler M, Gisslinger H. TGF-β1 induces bone marrow reticulin fibrosis in hairy cell leukaemia. J Clin Invest. 2004;113(5):676-85. [crossref][PubMed]
22.
Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukaemia and myelofibrosis has an increased vascularity. Am J Pathol. 2000;157(1):15-19. [crossref][PubMed]
23.
Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukaemias and myelodysplastic syndrome. Blood. 2000;96(6):2240-45. [crossref][PubMed]
24.
Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukaemia. Blood. 2002;100(9):3344-51. [crossref][PubMed]
25.
Ghannadan M, Wimazal F, Simonitsch I, Sperr WR, Mayerhofer M, Sillaber C, et al. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukaemia: Correlation between VEGF expression and the FAB category. Am J Clin Path. 2003;119(5):663-71. [crossref][PubMed]
26.
Wróbel T, Mazur G, Surowiak P, Wolowiec D, Jelen M, Kuliczkowsky K. increased expression of Vascular Endothelial Growth Factor (VEGF) in bone marrow of patients with Myeloproliferative Disorders (MPD). Pathol Oncol Res. 2003;9(3):170-73. [crossref][PubMed]
27.
Song M, Wang H, Ye Q. Increased circulating vascular endothelial growth factor in acute myeloid leukaemia patients: A systematic review and meta-analysis. Syst Rev. 2020;9(1):103. Available from: https://doi.org/10.1186/s13643-020- 01368-9. [crossref][PubMed]
28.
Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchy maltransition in cancer progression. Br J Cancer. 2008;99(9):1375-79. [crossref][PubMed]
29.
Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood). 2008;233(2):109-22. [crossref][PubMed]
30.
Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005;97(6):512-23. [crossref][PubMed]
31.
Erba BG, Gruppi C, Corada M, Pisati F, Rosti V, Bartalucci N, et al. Endothelial-to-mesenchymal transition in bone marrow and spleen of primary myelofibrosis. Am J Pathol. 2017;187(8):1879-92. [crossref][PubMed]
32.
Suetterlin R, Baschong W, Hubert Laeng R. Immunofluorescence and confocal laser scanning microscopy of chronic myeloproliferative disorders on archival formaldehyde-fixed bone marrow. J Histochem Cytochem. 2004;52(3):347-54. [crossref][PubMed]
33.
Wu S, Du Y, Beckford J, Alachkar H. Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukaemia. J Transl Med. 2018;16(1):170. [crossref][PubMed]
34.
Ivaska J, Pallari HM, Nevo J, Eriksson JE. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res. 2007;313(10):2050-62. [crossref][PubMed]

DOI and Others

DOI: 10.7860/JCDR/2024/70304.20248

Date of Submission: Feb 23, 2024
Date of Peer Review: Apr 16, 2024
Date of Acceptance: Aug 10, 2024
Date of Publishing: Nov 01, 2024

AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? No
• For any images presented appropriate consent has been obtained from the subjects. NA

PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Feb 23, 2024
• Manual Googling: Apr 15, 2024
• iThenticate Software: Aug 09, 2024 (14%)

ETYMOLOGY: Author Origin

EMENDATIONS: 8

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com